Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions.
Non-Hodgkin's lymphomas (NHLs) are malignant neoplasms which are clinically and biologically diverse. Their incidence is constantly increasing and despite treatment advances, there is a need for novel targeted therapies. Here, we identified Lectin-like transcript 1 (LLT1) as a biomarker of germinal center (GC)-derived B-cell NHLs. LLT1 identifies GC B cells in reactive tonsils and lymph nodes and its expression is maintained in B-cell NHLs which derive from GC, including Burkitt lymphoma (BL), follicular lymphoma (FL), and GC-derived diffuse large B-cell lymphoma (DLBCL). We further show that LLT1 expression by tumors dampens natural killer (NK) cell functions following interaction with its receptor CD161, uncovering a potential immune escape mechanism. Our results pinpoint LLT1 as a novel biomarker of GC-derived B-cell NHLs and as a candidate target for innovative immunotherapies.
['Germain|Claire|C|', 'Guillaudeux|Thierry|T|', 'Galsgaard|Elisabeth D|ED|', 'Hervouet|Catherine|C|', 'Tekaya|Nedra|N|', 'Gallouet|Anne-Sophie|AS|', 'Fassy|Julien|J|', 'Bihl|Franck|F|', 'Poupon|Gwenola|G|', 'Lazzari|Anne|A|', 'Spee|Pieter|P|', 'Anjuère|Fabienne|F|', 'Pangault|Céline|C|', 'Tarte|Karin|K|', 'Tas|Patrick|P|', 'Xerri|Luc|L|', 'Braud|Veronique M|VM|']
natural killer cells LLT1 germinal center CD161 non-Hodgkin's B-cell lymphoma